Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Clinical Genetics

The Diagnostic Journey: Genetics, Labs, and Criteria

At a Glance

Congenital generalized lipodystrophy is diagnosed by combining a child’s pattern of generalized fat loss and other clinical signs with metabolic blood tests, genetic testing of the four main CGL genes, and sometimes body-fat imaging.

Diagnosing Congenital Generalized Lipodystrophy (CGL)—also known as Berardinelli-Seip Syndrome—is a process that combines what a doctor sees (clinical criteria), what the lab finds (metabolic markers), and what the DNA reveals (genetic testing) [1][2]. Because this condition is so rare, ensuring the diagnostic “checklist” is complete is vital for getting the right care.

The Clinical Diagnostic Rules

Doctors often use a specific set of “major” and “minor” criteria to make a clinical diagnosis. Usually, a child is diagnosed if they meet three major criteria or two major and two minor criteria [3][4]. These clinical criteria are supportive frameworks, however, and their composition varies by guideline; diagnosis should be made by a specialist using the whole clinical picture, molecular results, and the exclusion of mimics.

Common Major Criteria Include:

  • Generalized Fat Loss: A near-total absence of fat under the skin from birth or early infancy [3].
  • Muscular Appearance: A very defined, prominent musculature due to lack of fat and enlarged muscles (muscular hypertrophy) [3][5].
  • Acromegaloid Features: Changes in growth, such as large hands or feet, or a prominent jaw [3].
  • Enlarged Liver: Known as hepatomegaly, caused by fat being stored in the liver instead of fat cells [6].
  • High Triglycerides: Extremely high levels of fats in the blood [3].

Common Minor Criteria Include:

  • Heart Issues: Such as an enlarged heart muscle (hypertrophic cardiomyopathy) [7].
  • Advanced Bone Age: Bones appearing “older” on an X-ray than the child’s actual age [8].
  • Skin Changes: Dark, velvety patches of skin (acanthosis nigricans) indicating insulin resistance [9].

Genetic Testing: The “Completeness Checklist”

Genetic testing is the gold standard for confirming CGL and identifying its subtype (CGL1–4). However, standard “sequencing” tests can sometimes miss critical information [1][10].

When reviewing your child’s genetic reports, ensure these three elements were included:

  1. Multigene Panel: The test should look at all four primary CGL genes: AGPAT2, BSCL2, CAV1, and PTRF [1].
  2. Copy-Number Variation (CNV) Analysis: This is a specialized look for “missing” or “extra” chunks of DNA that sequencing might skip [11][10].
  3. Inconclusive Results: If a test only finds one genetic change, or a variant of uncertain significance, discuss with a clinical geneticist whether expanded copy-number variation (CNV) or structural-variant analysis (such as testing for a BSCL2 Exon 3 deletion using MLPA) is clinically indicated [10][12].

Understanding the Metabolic Lab Reports

Your child will have regular blood work to monitor their metabolic health. These numbers tell the story of how the body is handling energy without enough fat cells. Keep in mind that reference ranges are age-specific [13][14].

  • Leptin: This hormone is made by fat cells. In CGL, leptin is typically very low in untreated generalized lipodystrophy. Note that leptin levels vary by assay, age, and residual fat, but a severe deficiency is a major contributor to the intense hunger seen in CGL [15][16].
  • Triglycerides: These are fats in the blood. Children with untreated CGL often have levels well above normal pediatric ranges, carrying a major risk for acute pancreatitis [14][17].
  • Fasting Insulin & Glucose: These measure how hard the body is working to manage sugar. High insulin (hyperinsulinemia) is common early on, even if blood sugar (glucose) remains normal [14][18].
  • HbA1c: This provides a 3-month average of blood sugar levels. It helps track if insulin resistance is progressing toward diabetes [13][9].

Tools for Measuring Body Fat

Because CGL is defined by a lack of fat, doctors sometimes use imaging or physical assessments to map where fat is (or isn’t) located. This helps distinguish CGL from other conditions [19][1].

  • DEXA Scan: Uses low-dose X-rays to measure total body fat percentage [20][21].
  • Whole-Body MRI: This is the most detailed way to see “hidden” fat. It can show if fat is preserved in specific areas like the palms, soles, or eye sockets [8][1]. Note that whole-body MRI is not routinely required for every infant.
  • Skinfold Measurements: A simple physical test using calipers. In children with CGL, the skinfold thickness (especially at the calf) is typically profoundly low (sometimes noted in studies below 8 mm, though reference ranges are age-specific) [22].

Common questions in this guide

How is congenital generalized lipodystrophy diagnosed in a child?
Doctors combine the child’s pattern of fat loss and physical findings with metabolic blood tests and genetic results. A clinical framework may support diagnosis when there are three major findings or two major plus two minor findings, but criteria vary and a specialist must consider the whole picture and rule out similar conditions.
What should a genetic test for CGL look for?
Testing should include a panel of the four main CGL genes—AGPAT2, BSCL2, CAV1, and PTRF—along with copy-number analysis for missing or extra DNA segments. If testing finds only one change or a result whose meaning is uncertain, a clinical geneticist may recommend additional deletion or structural-variant testing.
Does a low leptin level confirm CGL?
Leptin is usually very low in untreated generalized lipodystrophy because it is made by fat cells, and severe deficiency can contribute to intense hunger. The result must be interpreted with age, the test method, and remaining body fat; it is one part of the evaluation rather than a stand-alone confirmation.
Which blood tests are important when evaluating CGL?
Doctors commonly monitor triglycerides, fasting insulin and glucose, and HbA1c. High insulin may appear while glucose is still normal, very high triglycerides can increase pancreatitis risk, and all results should be compared with age-specific ranges.
How do doctors measure body fat in a child with suspected CGL?
DEXA estimates total body-fat percentage, whole-body MRI shows fat preserved in areas such as the palms, soles, or eye sockets, and skinfold calipers measure fat thickness at the skin. MRI is not routinely needed for every infant, so the care team chooses the method based on the child’s needs.
What if my child’s CGL genetic test finds only one variant?
One genetic change or a variant of uncertain significance may leave the result inconclusive. A clinical geneticist can review whether the test included copy-number analysis and whether additional structural-variant or deletion testing, such as MLPA for a BSCL2 exon 3 deletion, is appropriate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you walk me through which specific major and minor criteria my child meets for a clinical diagnosis of Berardinelli-Seip Syndrome?
  2. 2.Did our genetic testing include copy-number variation (CNV) or deletion analysis to look for missing pieces of the BSCL2 gene, such as an exon 3 deletion?
  3. 3.If only one genetic variant was found, what are the next steps to ensure we haven't missed a second deletion or mutation?
  4. 4.What are my child's current fasting triglyceride and insulin levels, and how do they compare to the targets for a child with CGL?
  5. 5.Which imaging method—DEXA, MRI, or skinfold measurements—will we use to monitor my child's body composition over time?
  6. 6.Is my child's leptin level low enough to confirm the diagnosis, and how does this level affect their hunger and metabolism?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy.

    Craveiro Sarmento AS, Ferreira LC, Lima JG, et al.

    Mutation research. Reviews in mutation research 2019; (781()):30-52 doi:10.1016/j.mrrev.2019.03.005.

    PMID: 31416577
  2. 2

    Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.

    Vatier C, Vantyghem MC, Storey C, et al.

    Current medical research and opinion 2019; (35(3)):543-552 doi:10.1080/03007995.2018.1533459.

    PMID: 30296183
  3. 3

    Berardinelli-Seip Congenital Lipodystrophy Discovered Following a STEMI Event.

    Beires F, Greenfield H, Brito da Silva J, et al.

    European journal of case reports in internal medicine 2022; (9(12)):003658 doi:10.12890/2022_003658.

    PMID: 36632537
  4. 4

    Identifying congenital generalized lipodystrophy using deep learning-DEEPLIPO.

    da Cunha Olegario NB, da Cunha Neto JS, Barbosa PCS, et al.

    Scientific reports 2023; (13(1)):2176 doi:10.1038/s41598-023-27987-5.

    PMID: 36750605
  5. 5

    Congenital generalized lipodystrophies--new insights into metabolic dysfunction.

    Patni N, Garg A

    Nature reviews. Endocrinology 2015; (11(9)):522-34 doi:10.1038/nrendo.2015.123.

    PMID: 26239609
  6. 6

    Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy.

    Santos JL, Cortés VA

    Obesity reviews : an official journal of the International Association for the Study of Obesity 2021; (22(1)):e13114 doi:10.1111/obr.13114.

    PMID: 33030294
  7. 7

    Metabolic and other morbid complications in congenital generalized lipodystrophy type 4.

    Akinci G, Alyaarubi S, Patni N, et al.

    American journal of medical genetics. Part A 2024; (194(6)):e63533 doi:10.1002/ajmg.a.63533.

    PMID: 38234231
  8. 8

    Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy.

    Altay C, Seçil M, Demir T, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2017; (23(6)):428-434 doi:10.5152/dir.2017.17019.

    PMID: 29044029
  9. 9

    Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants.

    Liu Y, Li D, Ding Y, et al.

    European journal of medical genetics 2019; (62(9)):103542 doi:10.1016/j.ejmg.2018.09.009.

    PMID: 30266686
  10. 10

    Novel compound heterozygous variant of BSCL2 identified by whole exome sequencing and multiplex ligation‑dependent probe amplification in an infant with congenital generalized lipodystrophy.

    Xie B, Fan X, Lei Y, et al.

    Molecular medicine reports 2020; (21(6)):2296-2302 doi:10.3892/mmr.2020.11036.

    PMID: 32236581
  11. 11

    Targeted massively parallel sequencing for congenital generalized lipodystrophy.

    Costa-Riquetto AD, Santana LS, Caetano LA, et al.

    Archives of endocrinology and metabolism 2021; (64(5)):559-566.

    PMID: 34033296
  12. 12

    A New Compound Heterozygous Mutation Of BSCL2 In A Chinese Zhuang Ethnic Family With Congenital Generalized Lipodystrophy.

    Qin YY, Zhang X, Xiang LQ, et al.

    Diabetes, metabolic syndrome and obesity : targets and therapy 2019; (12()):2583-2587 doi:10.2147/DMSO.S207293.

    PMID: 31824185
  13. 13

    Early Left Ventricular Systolic Dysfunction Detected by Two-Dimensional Speckle-Tracking Echocardiography in Young Patients with Congenital Generalized Lipodystrophy.

    Liberato CBR, Olegario NBDC, Fernandes VO, et al.

    Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):107-115 doi:10.2147/DMSO.S233667.

    PMID: 32021357
  14. 14

    Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy.

    Papendieck L, Araujo MB

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(1)):77-83 doi:10.1515/jpem-2017-0355.

    PMID: 29267171
  15. 15

    A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature.

    Mancioppi V, Daffara T, Romanisio M, et al.

    Frontiers in endocrinology 2023; (14()):1212729 doi:10.3389/fendo.2023.1212729.

    PMID: 37501786
  16. 16

    Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

    Diker-Cohen T, Cochran E, Gorden P, Brown RJ

    The Journal of clinical endocrinology and metabolism 2015; (100(5)):1802-10 doi:10.1210/jc.2014-4491.

    PMID: 25734254
  17. 17

    Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review.

    Subramanian S, Soran H, Sikora Kessler A, et al.

    European journal of internal medicine 2025; 106648 doi:10.1016/j.ejim.2025.106648.

    PMID: 41444050
  18. 18

    Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.

    Adiyaman SC, V Schnurbein J, De Laffolie J, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2022; (35(7)):946-952 doi:10.1515/jpem-2022-0022.

    PMID: 35405042
  19. 19

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  20. 20

    "Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers.

    Meral R, Ryan BJ, Malandrino N, et al.

    Diabetes care 2018; (41(10)):2255-2258 doi:10.2337/dc18-0978.

    PMID: 30237235
  21. 21

    Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy.

    Lima JG, Nobrega LH, de Lima NN, et al.

    Diabetology & metabolic syndrome 2016; (8()):23 doi:10.1186/s13098-016-0140-x.

    PMID: 26985241
  22. 22

    Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study.

    da Cruz Paiva Lima GE, de Moura Lopes FK, Araújo JS, et al.

    Diabetology & metabolic syndrome 2025; (17(1)):388 doi:10.1186/s13098-025-01934-y.

    PMID: 41074178

This page is for informational purposes only and does not constitute medical advice. A clinical geneticist and your child's metabolic care team should interpret the diagnostic criteria, laboratory results, and genetic report.

Get notified when new evidence is published on Congenital generalized lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.